Ovid Therapeutics (OVID) Total Liabilities (2016 - 2026)

Ovid Therapeutics has reported Total Liabilities for 11 years, with the latest figure at $27.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 22.26% year-over-year to $27.4 million; the trailing twelve-month figure through Mar 2026 stood at $27.4 million (up 22.26% YoY), and the FY2025 full-year result was $20.3 million, down 15.32% from the prior year.
• Total Liabilities for Q1 2026 stood at $27.4 million, up from $20.3 million in the prior quarter.
• The five-year high for Total Liabilities was $56.2 million in Q4 2023, with the low at $19.2 million in Q3 2025.
• Historically, Total Liabilities has averaged $27.6 million across 5 years, with a median of $23.9 million in 2024.
• Annual changes were most pronounced in 2023 — Total Liabilities surged 144.55% — and 2025, when it tumbled 58.04%.
• Ovid Therapeutics' Total Liabilities stood at $23.0 million in 2022, then surged by 144.55% to $56.2 million in 2023, then slumped by 57.42% to $23.9 million in 2024, then retreated by 15.32% to $20.3 million in 2025, then jumped by 34.95% to $27.4 million in 2026.
• The last three Total Liabilities figures came in at $27.4 million (Q1 2026), $20.3 million (Q4 2025), and $19.2 million (Q3 2025), per Business Quant data.